Targeted prostate biopsies for a histogram of the index lesion

Current Opinion in Urology

Volumn 23, Issue 2, 2013, Pages 118-122

  Ukimura, Osamu ^a,b   Gill, Inderbir S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

biopsy; MRI; prostrate cancer; ultrasound

Indexed keywords

ANATOMICAL VARIATION; CANCER LOCALIZATION; CANCER MODEL; CLINICAL DECISION MAKING; DIAGNOSTIC ACCURACY; HISTOGRAM; HISTOPATHOLOGY; HUMAN; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; THREE DIMENSIONAL IMAGING; TRANSRECTAL ULTRASONOGRAPHY;

BIOPSY, LARGE-CORE NEEDLE; HUMANS; IMAGE-GUIDED BIOPSY; MALE; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84873412698     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32835d4dc8     Document Type: Review

References (38)

1. Ukimura O, Coleman JA, de la Taille A, et al. Contemporary role of systematic prostate biopsies: Indications, techniques, and implications for patient care. Eur Urol 2013; 63:214-230.
2. Moore CM, Robertson NL, Arsanious N, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: A systematic review. Eur Urol 2013; 63:125-140.
3. Hung AJ, Abreu AL, Shoji S, et al. Robotic transrectal ultrasonography during robot-assisted radical prostatectomy. Eur Urol 2012; 62:341-348.
4. .Bahn D, de Castro Abreu AL, Gill IS, et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 2012; 62:55-63. This study provides encouraging outcomes of focal cryotherapy with intermediate follow-up period up to 8 years. Over 80% of this selected cohort for focal therapy had targeted-biopsy proven image-visible cancer to allow 3D cancer mapping of the index lesion for precise therapeutic target.
5. Karavitakis M, Winkler M, Abel PD, et al. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: Implications for focal therapy. Prostate Cancer Prostatic Dis 2011; 14:46-52.
6. Ukimura O, Magi-Galluzzi C, Gill IS. Real-time transrectal ultrasound guidance during laparoscopic radical prostatectomy: Impact on surgical margins. J Urol 2006; 175:1304-1310.
7. Stamey TA, McNeal JM, Wise AM, Clayton JL. Secondary cancers in the prostate do not determine PSA biochemical failure in untreated men undergoing radical retropubic prostatectomy. Eur Urol 2001; 39 (Suppl. 4):22-23. (Pubitemid 32429649)
8. Noguchi M, Stamey TA, McNeal JE, Nolley R. lack of significance of secondary cancers. J Urol 2003; 170 (2 Pt 1):459-463.
9. Ahmed HU. The index lesion and the origin of prostate cancer. N Eng J Med 2009; 361:1704-1706.
10. Haffner J, Potiron E, Bouyeacute; S, et al. Peripheral zone prostate cancers: Location and intraprostatic patterns of spread at histopathology. Prostate 2009; 69: 276-282.
11. Bott SRJ, Ahmed HU, Hindley RG, et al. The index lesion and focal therapy: An analysis of the pathological characteristics of prostate cancer. BJU Int 2010; 106:1607-1611.
12. Washington SL, Bonham M, Whitson JM, et al. Transrectal ultrasonographyguided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer. BJU Int 2012; 110:50-55.
13. Barzell WE, Melamed MR, Cathcart P, et al. Identifying candidates for active surveillance: An evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer. J Urol 2012; 188:762-767.
14. Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009; 27:4321-4326.
15. Toi A, Neill MG, Lockwood GA, et al. The continuing importance of transrectal ultrasound identification of prostatic lesions. J Urol 2007; 177:516-520. (Pubitemid 46054011)
16. Trottier G, Roobol MJ, Lawrentschuk N, et al. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. BJU Int 2011; 108 (8 Pt 2):E237-E244.
17. Seitz M, Gratzke C, Schlenker B, et al. Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer. Urol Oncol 2011; 29:295-301.
18. Strazdina A, Krumina G, Sperga M. The value and limitations of contrastenhanced ultrasound in detection of prostate cancer. Anticancer Res 2011; 31:1421-1426.
19. Halpern EJ, Gomella LG, Forsberg F, et al. Contrast enhanced transrectal ultrasound for the detection of prostate cancer: A randomized, double-blind trial of dutasteride pretreatment. J Urol 2012; 188:1739-1745.
20. Walz J, Marcy M, Pianna JT, et al. Identification of the prostate cancer index lesion by real-time elastography: Considerations for focal therapy of prostate cancer. World J Urol 2011; 29:589-594.
21. Brock M, von Bodman C, Sommerer F, et al. Comparison of real-time elastography with grey-scale ultrasonography for detection of organ-confined prostate cancer and extra capsular extension: A prospective analysis using whole mount sections after radical prostatectomy. BJU Int 2011; 108 (8 Pt 2): E217-E222.
22. Brock M, von Bodman C, Palisaar RJ, et al. The impact of real-time elastography guiding a systematic prostate biopsy to improve cancer detection rate: A prospective study of 353 patients. J Urol 2012; 187:2039-2043.
23. Villers A, Puech P, Mouton D, et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: Correlation with radical prostatectomy findings. J Urol 2006; 176 (6 Pt 1):2432-2437. (Pubitemid 44665992)
24. Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 2012; 61:177- 184.
25. Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, et al. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score - 33 6 upon schematic TRUS-guided biopsy: A radical prostatectomy correlated series. Invest Radiol 2012; 47:153-158.
26. Vargas HA, Akin O, Afaq A, et al. Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol 2012; 188:1732-1738.
27. Vourganti S, Rastinehad A, Yerram NK, et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol 2012; 188:2152-2157. doi: 10.1016/j.juro.2012.08.025.
28. Ukimura O, Desai MM, Palmer S, et al. 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J Urol 2012; 187:1080-1086.
29. .Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for localized unifocal and multifocal prostate cancer: A prospective development study. Lancet Oncol 2012; 13:622-632.
30. This study reported initial lesion targeted focal therapy using HIFU. The index lesion was visible by multiparametric MRI and confirmed by 3D mapping biopsy with external template.
31. Ukimura O, Troncoso P, Ramirez EI, Babaian RJ. Prostate cancer staging: Correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension. J Urol 1998; 159:1251-1259. (Pubitemid 28172808)
32. Mazaheri Y, Hricak H, Fine SW, et al. Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: Correlation with pathologic tumor volume. Radiology 2009; 252:449-457.
33. Ukimura O, Lewandowski P-M, Leslie S, et al. 'Index lesion' mapping by 3D image-guided TRUS biopsy: Correlation with step-sectioned radical prostatectomy (RP) specimens. The 2012 AUA Annual Meeting, Mon 19-23, 2012; Atlanta. J Urol; Suppl. Abstract 505; 2012.
34. .Simmons LA, Autier P, Zaacute;tura F, et al. Detection, localisation and characterization of prostate cancer by prostate HistoScanning (TM). BJU Int 2012; 110:28-35. This study reported an encouraging technology to create predicted 3D cancer model of the clinically important cancer (greater than 0.5 or 0.2 ml in volume) using computer-assisted diagnosis of 3D TRUS volume data.
35. Salomon G, Spethmann J, Beckmann A, et al. Accuracy of HistoScanning for the prediction of a negative surgical margin in patients undergoing radical prostatectomy. BJU Int 2012. doi: 10.1111/j.1464-410X.2012.11396.x. [Epub ahead of print
36. .Groenendaal G, Borren A, Moman MR, et al. Pathologic validation of a model based on diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging for tumor delineation in the prostate peripheral zone. Int J Radiat Oncol Biol Phys 2012; 82:e537-e544. This study reported a novel color-coded cancer delineation technology using logistic voxelwise prediction with 2.5mm in dimension based on diffusionweighted and contrast-enhanced MRI.
37. Turkbey B, Mani H, Aras O, et al. Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol 2012; 188:1157-1163.
38. Robertson NL, Moore CM, Ambler G, et al. MAPPED study design: A 6-month randomised controlled study to evaluate the effect of dutasteride on prostate cancer volume using magnetic resonance imaging. Contemp.Clin.Trials 2012; 34:80-89. doi: 10.1016/j.cct.2012.10.003